Allogeneic Stem Cell Transplantation in Myelofibrosis

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Myeloproliferative neoplasms (MPN) encompass BCR-ABL1-negative disorders like primary myelofibrosis (MF).
• These clonal stem cell disorders manifest with anemia, splenomegaly, and debilitating constitutional symptoms.
• While treatments offer symptom relief, allogeneic stem cell transplantation (HCT) is the sole potentially curative option.

Purpose of the Study:

• To review recent data on peritransplantation factors affecting HCT outcomes in MF patients.
• To explore emerging therapeutic areas, including Janus kinase (JAK) inhibitors in HCT for MF.
• To provide conclusions based on current literature regarding MF management and HCT.

Main Methods:

• Literature review of recent data on myelofibrosis and allogeneic stem cell transplantation.
• Analysis of peritransplantation factors impacting patient outcomes.
• Evaluation of novel therapeutic strategies, including JAK inhibitors, in the context of HCT.

Main Results:

• HCT is the only potentially curative treatment for myelofibrosis (MF).
• Patient prognosis, age, comorbidities, and functional status are critical for HCT decision-making.
• Peritransplantation factors and novel therapies like JAK inhibitors significantly influence HCT outcomes.

Conclusions:

• Optimizing peritransplantation factors is crucial for improving HCT success in MF.
• The integration of JAK inhibitors presents a promising new therapeutic avenue in HCT for MF.
• Further research is needed to refine HCT protocols and therapeutic strategies for MF.